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Integrative analyses of transcriptome sequencing identify novel
functional lncRNAs in esophageal squamous cell carcinoma
C-Q Li1,2,10, G-W Huang1,10, Z-Y Wu3,10, Y-J Xu4, X-C Li2, Y-J Xue1, Y Zhu1, J-M Zhao1,2, M Li2, J Zhang2, J-Y Wu1, F Lei1, Q-Y Wang1,2, S Li4,
C-P Zheng3, B Ai2, Z-D Tang2, C-C Feng2, L-D Liao1, S-H Wang3, J-H Shen3, Y-J Liu2, X-F Bai2, J-Z He1, H-H Cao1, B-L Wu1, M-R Wang5,
D-C Lin6, HP Koeffler6,7,8, L-D Wang9, X Li4, E-M Li1 and L-Y Xu1
Long non-coding RNAs (lncRNAs) have a critical role in cancer initiation and progression, and thus may mediate oncogenic or tumor
suppressing effects, as well as be a new class of cancer therapeutic targets. We performed high-throughput sequencing of RNA
(RNA-seq) to investigate the expression level of lncRNAs and protein-coding genes in 30 esophageal samples, comprised of 15
esophageal squamous cell carcinoma (ESCC) samples and their 15 paired non-tumor tissues. We further developed an integrative
bioinformatics method, denoted URW-LPE, to identify key functional lncRNAs that regulate expression of downstream protein-
coding genes in ESCC. A number of known onco-lncRNA and many putative novel ones were effectively identified by URW-LPE.
Importantly, we identified lncRNA625 as a novel regulator of ESCC cell proliferation, invasion and migration. ESCC patients with
high lncRNA625 expression had significantly shorter survival time than those with low expression. LncRNA625 also showed specific
prognostic value for patients with metastatic ESCC. Finally, we identified E1A-binding protein p300 (EP300) as a downstream
executor of lncRNA625-induced transcriptional responses. These findings establish a catalog of novel cancer-associated functional
lncRNAs, which will promote our understanding of lncRNA-mediated regulation in this malignancy.
Oncogenesis (2017) 6, e297; doi:10.1038/oncsis.2017.1; published online 13 February 2017
INTRODUCTION
Esophageal squamous cell carcinoma (ESCC) is one of the more
prevalent and lethal cancers worldwide.1,2 In eastern Asia, ESCC is
associated with high morbidity and mortality compared with
Western countries.1,2 To date, ESCC-related research has primarily
focused on the deregulation of protein-coding genes (PCGs) and
microRNAs to identify oncogenes and tumor suppressors, thereby
missing long non-coding RNAs (lncRNAs).3,4 LncRNAs are an RNA
species 4200 bp in length and expressed in a tissue-specific
manner. Several well-described examples have shown that
lncRNAs have critical roles in cancer initiation and progression,
and thus may mediate oncogenic or tumor suppressing effects,
as well as comprise a new class of cancer therapeutic targets.5–7
Examples include the increased expression of HOTAIR in
metastatic breast cancer,5 oncogenicity and tumor-suppressive
properties of H19 in different cancers,6 ANRIL-induced epigenetic
silencing of p15 in leukemia,7 and the ability of MALAT1 to confer
high metastatic potential in non-small cell lung cancer.8 In
contrast to these well-described examples, little is known about
the functions of most lncRNAs in caner initiation and progression.
For example, ESCCAL-1 was found to be an onco-lncRNA in
esophageal cancer development, and high expression of BC200 or
MALAT1 has been shown to be a novel predictive marker for ESCC
patients who received radical resection.9–11 Overall, a handful of
lncRNAs have documented roles in ESCC.4,9–17
Next-generation transcriptome sequencing (RNA-seq) has pro-
vided a method to delineate the entire set of transcriptional
aberrations in a disease, including lncRNAs and PCGs. For
example, using RNA-seq to analyze prostate cancer tissues, the
landscape of lncRNAs in prostate cancer has been recently defined
and notably includes prostate cancer functional lncRNAs, such as
PCA118 and SChLAP1.19 In the case of ESCC, Ma et al.20 has applied
transcriptome sequencing to ESCC tissues from three patients and
adjacent non-tumor tissues. However, because the existing
transcriptome sequencing for ESCC focuses on research of PCGs,
most of the functional lncRNAs in ESCC have yet to be identified.
The functions of lncRNAs are closely associated with their
abundance of transcripts and downstream target PCGs directly
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or indirectly regulated by them.21 LncRNA-induced transcriptional
dysregulation of target PCGs has become an effective strategy to
identify key functional lncRNAs and several successful methods
have been developed.11,22,23 For example, a random walk strategy
has been used to search for candidate prostate cancer-related
lncRNAs in the lncRNA-PCG bipartite network based on sample
correlation, and a lncRNA-PCG co-expression network has been
constructed to predict the functions of lncRNAs.22 A limitation of
these methods is the requirement for known cancer lncRNAs to
serve as seeds. However, for many diseases such as ESCC, only a
few known lncRNAs are available to be used as seeds, which
decreases the predictive power for a disease. In addition, methods
based on known lncRNAs as seeds also tend to identify
neighborhood lncRNAs of well-studied cancer lncRNAs, and thus
lack ability to identify novel functional lncRNAs.
Here, we perform RNA-seq to investigate expression levels of
lncRNAs and PCGs in 30 esophageal samples (15 paired ESCC and
non-tumor esophageal tissues). We further developed a method,
denoted URW-LPE (for Unsupervised Random Walk method
with each dysregulated LncRNA/PCG as a seed and extended
co-Expression relation as an edge), to identify novel potential
functional lncRNAs based on global lncRNA-PCG network
information.
RESULTS
Expression analysis of ESCC-related lncRNAs and coding genes
RNA-seq was performed on 30 esophageal samples (15 paired
ESCC and non-tumor esophageal tissues, Supplementary Table 1)
from Chinese patients. Sequencing reads were mapped against
the human genome assembly (NCBI Build 37) using Tophat
(v2.0.6). For each sample, on average, 62.30 million reads were
mapped to known human genes (Supplementary Table 2).
Congruent with previous reports, lncRNAs were expressed at
levels lower than PCGs (Figure 1a), with expression levels of 75%
lncRNAs being less than 10 RPKM (Figure 1b). We identified 1226
differentially expressed lncRNAs between tumors and non-tumor
matched samples (Figure 1c; fold change 42 or o½, and a
DESeq FDR value o0.25). These differentially expressed lncRNAs
made up 4.3% of all expressed lncRNAs and PCGs, of which
lncRNA made up 41.2% of all differential lncRNAs (Figure 1d). With
this same criterion, we identified 2996 differentially expressed PCGs,
of which 1834 were upregulated and 1162 were downregulated.
We focused on these differentially expressed lncRNAs and PCGs
(fold change 42 or fold change o½, and a DESeq FDR value
o0.25). Hierarchical clustering analysis on the expression profile
of 1,226 differentially expressed lncRNAs exhibited a 2-branch
partition with the 15 ESCC tumor samples clustered together and
well separated from their matched non-tumor controls (Figure 1e).
Similar results were obtained when using the 2,996 differentially
expressed PCGs (Supplementary Figure 1). To validate the utility of
the RNA-seq data to identify cancer-related lncRNAs, we examined
the expression patterns of 8 literature-evidenced ESCC-related
lncRNAs (top panel in Figure 1c). Notably, RNA-seq analysis
revealed that six of 8 known ESCC-related lncRNAs showed a
consistently upregulated expression pattern. Three known ESCC
lncRNAs, comprising HOTAIR,15 ANRIL,16 and SOX2OT,17 showed
statistically significantly differential expression between tumor
and non-tumor samples (FDR values of DESeq were 5.51E-05,
0.0048 and 0.21, respectively). Results of expression at the exon
level demonstrated that our RNA-seq was capable of correctly
measuring expression of lncRNAs (Supplementary Figure 2).
The upregulation of another three known ESCC lncRNAs,
comprising PCA1,24 TUG125 and H19,26 were also consistent with
the upregulation reported by other groups.24–26 Interestingly, we
found that two cancer-related lncRNAs PVT127 and WT1-AS,28
which were not reported in ESCC, displayed differential expression
based on our RNA-seq analysis. MIR31HG,29 a tumor-suppressive
lncRNA known to be downregulated in glioblastoma, showed
increased expression in ESCC, suggesting complex and context-
dependent functions of lncRNAs in different cancer types.
DLX6-AS1, LINC00162 and NPPA-AS1, which were reported to
function in development, narcolepsy and modulation of blood
pressure,30–32 showed differential expression between ESCC tissue
samples and paired non-tumor tissues, suggesting their function
in ESCC.
Identification of functional lncRNAs in ESCC
LncRNAs do not encode protein, but often either directly or
indirectly regulate transcription, splicing and translation of
downstream target PCGs.3 These reports prompted us to test
the correlation between the expression of lncRNA and PCG to
pinpoint key lncRNAs. We identified 4,554 pair significant
co-expression relationships between 615 differential lncRNAs
and 2182 differential PCGs. We further constructed an extended
lncRNA-PCG co-expression network based on differentially
expressed lncRNAs/PCGs (Figure 2a). Edges in the network were
constructed if two molecules were significantly co-expressed (FDR
o1.0e-7) or they had direct protein-protein or lncRNA-protein
interaction relationship in the HPRD or NPInter databases
(Materials and methods section). In the final network, 615 lncRNAs
and 2182 PCGs with 16 809 edges remained. As shown in
Figure 2a, the upregulated nodes exceeded the downregulated
nodes. Four hundred fifty (73.17%) lncRNAs and 1456 (66.72%)
PCGs were upregulated in the network, suggesting that lncRNAs
might stimulate downstream targets mainly through inducing
mechanisms. Topological analysis showed that the network
displayed a power-law distribution and module tendency
(Supplementary Figure 3). Indeed, many lncRNAs and PCGs closely
gathered together to form active modules (for example, regions I
and II in Figure 2a). Network active analysis using the jActive
method, a widely used active module mining method
(http://www.cytoscape.org/), identified a highly active subnetwork
module (Figure 2b) and the lncRNAs and PCGs in the module were
mostly located in region I of the network. PCGs in the network
were significantly associated with cancer-related functions
(Figure 2c).
To identify more effectively the lncRNAs that are able to
regulate the expression of downstream PCGs from our extended
lncRNA-PCG co-expression network, we developed an unsuper-
vised random walk, denoted URW-LPE, with each dysregulated
lncRNA/PCG as a seed (Figure 2d; Materials and methods section).
A lncRNA will obtain a high score when it is highly differential and
closely associated with highly differential PCGs from the global
network view. A total of 615 differential lncRNAs in the network
received the URWScore. Multiple known oncogenic lncRNAs were
highly ranked according to URWScore, compared with their FC
value, validating the URW-LPE procedure (Table 1 and Figure 2e).
A good example is HOTAIR, a well-characterized ESCC lncRNA.
HOTAIR was ranked 35th, according to the URWScore, but was
only ranked 93rd according to the FC value (Table 1). The lncRNA
DLX6-AS1 was ranked 31st by URW-LPE, but only ranked 199th
according to its FC value (Table 1). The lncRNA in lung cancer
tissues is significantly higher compared with paired adjacent
normal lung tissues.31 Moreover, DLX6-AS1 might be a novel
therapeutic target for lung cancer patients because it appears to
enhance cancer invasion and metastasis.31 Taken together, the
top-ranked lncRNAs, identified by URW-LPE, have potential to
have novel functional roles in ESCC. Although the oncogenic
lncRNA ANRIL was ranked 241st by URW-LPE, its rank in URW-LPE
increased more than 100 compared with the rank according to FC
value (Table 1). The higher rank of this lncRNA, given by URW-LPE,
shows that our method has the ability for recalling functional
lncRNAs in ESCC.
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To comprehensively identify statistically significant lncRNAs,
FDR-corrected P-values for each lncRNA in the network were
calculated by URW-LPE through comparison of the URWScore, of
each lncRNA, with that of background distribution. With a strict
cutoff of FDR-corrected P-values o0.05 (corresponding to original
P-values o0.005), URW-LPE identified 63 statistically significant
lncRNAs (Supplementary Table 3). Of these lncRNAs, several
including HOTAIR,12–15 DLX6-AS1,31 AC130710.1.132 and WT1-AS,28
are known functional lncRNAs in cancer. For the most
well-characterized lncRNA HOTAIR, the URW-LPE analysis yielded
a P-value of 0.0015 (corrected to 0.025 by FDR) (Table 1).
In addition, DLX6-AS1,31,33 AC130710.1.1,32 and WT1-AS28 have
established functions in development,33 lung cancer,31 gastric
cancer32 and acute myeloid leukemia28 (Table 1). With a cutoff of
FDR-corrected P-values o0.1 (corresponding to original P-values
o0.023), 147 significant lncRNAs were identified (Supplementary
Table 3). For a downregulated functional lncRNA LINC00261,34 the
URW-LPE yielded a P-value of 0.00047 (corrected to 0.017 by FDR)
(Table 1). Jiang et al. demonstrated that LINC00261 enhances
FOXA2 activation by facilitating SMAD2/3 recruitment to the
FOXA2 promoter, and overexpression of FOXA2 is able to rescue
endoderm differentiation defects.34
Finally, we focused on novel lncRNAs not reported by the
existing studies to be associated with disease. From the
statistically significant lncRNAs in URW-LPE (FDR-corrected
P-values o0.05), three novel candidate upregulated lncRNAs
(lncRNA625, LINC00460 and AC093850.2) with high URWScores
and differential expression levels were selected for testing.
We investigated the expression level of candidate lncRNAs
in 120 paired ESCC tissues by PCR, quantitative reverse
transcriptase–PCR (qRT–PCR) analysis (Supplementary Tables 4
and 5). According to scatter plots, the expression trends of all
three lncRNAs were consistent with results of RNA-seq and were
significantly upregulated in ESCC samples (paired t-test; Figure 2f).
For most of lncRNAs not identified as significant by URW-LPE
(FDR-corrected P-values 40.1), statistically significant differences
were not obtained (paired t-test; Figure 2f), although the
expression trends of lncRNAs were consistent with results of
RNA-seq. These results demonstrate that novel functional lncRNAs
in ESCC identified as statistically significant by URW-LPE can be
confirmed by low-throughput experiment such as qRT–PCR.
Figure 1. Transcriptome sequencing of ESCC. (a) Average expression level of lncRNAs and PCGs. (b) Line graph showing that lncRNAs
are expressed less than PCGs. (c) Heat maps of the expression levels of lncRNAs that showed significant differential expression between
cancer and normal ESCC tissues. (d) Global overview of lncRNAs and PCGs in ESCC. Left pie chart displays differential and non-differential
lncRNA/PCG distribution in ESCC. Pie charts on the right display differentially expressed lncRNAs, respectively categorized as sense-intronic,
lincRNA, antisense, sense-overlapping, prime overlapping and processed transcripts. (e) Hierarchical clustering analysis on the expression
profile of 1226 differentially expressed lncRNAs. These lncRNAs were identified as differentially expressed when fold change42 or o½, and a
DESeq FDR value o0.25. The tree diagram exhibits a 2-branch partition with the 15 ESCC tumor samples clustered together and well
separated from their matched non-tumor controls.
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LncRNA625 modulates cancer cell proliferation, invasion and
migration via affecting downstream target PCGs
From these three lncRNAs, lncRNA625 displayed a high degree of
differential expression and a high URWScore (Figures 2e,f and 3a),
and it was selected for further functional characterization.
LncRNA625 expression was measured in various human esopha-
geal cancer cell lines and was found to be highly expressed in
KYSE150 and KYSE510 ESCC cells (Figure 3b). To delineate its
biological functions, endogenous lncRNA625 was downregulated
in KYSE150 and KYSE510 cells, and colony formation assays were
Figure 2. Identification of functional lncRNAs in ESCC via downstream target PCGs. (a) The extended lncRNA-PCG co-expression network. The
network is displayed using Cytoscape software according to the ‘spring’ layout. Node size is proportional to the degree of the node. Node
color reflects differential expression level. Nodes with a zigzag border line are differential PCGs after lncRNA625 knockdown in the network.
Interesting lncRNAs and PCGs are enlarged or labeled using their names. For example, nodes with a blue label are genes regulated by
lncRNA625. Circles with dashed lines in the network represent subnetwork modules with many highly upregulated lncRNAs and PCGs.
(b) An active subnetwork module in the lncRNA-PCG co-expression network. (c) PCGs in the lncRNA-PCG co-expression network are annotated
to Gene Ontology to identify their functions. (d) Schematic overview of URW-LPE. The top figure represents the data stream of URW-LPE, and
the bottom figure represents the running process of the random walk that is the core step of URW-LPE. (e) Fold change and URWScore value
of each lncRNA in the lncRNA-PCG co-expression network. Known disease lncRNAs and ESCC PCGs are labeled. (f) Scatter plots of the relative
expression levels of qRT–PCR of lncRNAs in an additional 120 paired ESCC patient samples. Note that because a lncRNA may not be identified
by qRT–PCR in the corresponding sample, the number of actual samples with expression level for each lncRNA was slightly less than the total
number of samples. Comparisons of the relative expression between tumor (T) and non-tumor (N) were performed using a paired t-test.
A P-value o0.05 was considered statistically significant. Black horizontal lines are means with s.e.m.
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performed. Importantly, we observed that proliferation of KYSE150
and KYSE510 cells was reduced by expressing a short hairpin RNA
against lncRNA625 (Figure 3c). Cell invasion and migration was also
inhibited following silencing of lncRNA625 (Figure 3d). Similar
results were obtained by small interfering RNAs (siRNA)-mediated
knockdown approaches (Supplementary Figure 4). Conversely,
ectopic expression of lncRNA625 in KYSE510 and SHEEC ESCC cells
resulted in enhanced migration (Figure 3e). An in vivo
tumorigenicity study in mice showed that the average tumor
volumes of stably transfected KYSE150-shlncRNA625 cells was
generally lower than control (Figure 3f, top panel). To further verify
the results, we measured tumor weight and found that the average
weight of tumors derived from stably transfected KYSE150-
shlncRNA625 cells was less than control (Figure 3f, bottom panel).
Taken together, these results indicate that lncRNA625 modulates
cancer cell proliferation, invasion and migration.
Table 1. Statistically significant functional lncRNAs predicted by URW-LPE
LncRNA ID LncRNA names URW Score FDR Rank (URW Score) Rank (FC)
ENSG00000228630 HOTAIRa 0.51 0.025 35 93
ENSG00000231764 DLX6-AS1a 0.52 0.023 31 199
ENSG00000236289 AC130710.1.1a 0.54 0.017 15 78
ENSG00000183242 WT1-ASa 0.52 0.022 28 1
ENSG00000259974 LINC00261a 0.47 0.055 73 107
ENSG00000240498 ANRILa 0.37 0.22 241 349
ENSG00000259756 RP11-625H11.2.1b 0.59 0.0077 3 1
ENSG00000233532 LINC00460b 0.50 0.032 43 130
ENSG00000230838 AC093850.2.1b 0.48 0.044 59 103
Abbreviations: lncRNA, long non-coding RNA; qRT–PCR, quantitative reverse transcriptase–PCR; URW, Unsupervised Random Walk method. aLiterature-
evidenced functional lncRNAs in cancer. bNovel functional lncRNAs, of which expression levels were confirmed by qRT–PCR in an additional 120 paired ESCC
patient samples.
Figure 3. LncRNA625 modulates cancer cell proliferation, invasion and migration via affecting downstream target PCGs. (a) Read distributions
of the RNA-seq gene model. (b) LncRNA625 expression in various human ESCC cells. (c) Colony formation of stably transfected KYSE150 and
KYSE510 stained with haematoxylin solution after incubation for 15 days. (d) Invasion and migration of KYSE150 and KYSE510 cells stably
transfected with shRNA against either lncRNA625 or with a scrambled RNA. (e) Migration of SHEEC cells detected at 48 h following
transfection with either lncRNA625 expression vector or control vector, and detection of lncRNA625 levels by real-time RT-PCR. Values are
mean± s.e.m. (f) LncRNA625 downregulation inhibited the proliferation of esophageal cancer cells. 1 × 106 KYSE150-shlncRNA625 or
shscramble cells were subcutaneously inoculated in the right flank of each BALB/c mouse (nu/nu) (n= 9) and after one week, tumor volumes
were measured every two days according to the formula: V= ab2/2 (‘a’ represents the length of tumor tissue and ‘b’ represents the width of
tumor tissue). The average weight of tumors was determined after mice were euthanized by CO2 inhalation.
Identification of novel functional lncRNAs
C-Q Li et al
5
Oncogenesis (2017), 1 – 14
Gene expression profiling by cDNA microarray analysis of the
lncRNA625 knockdown KYSE150 cell line indicated that lncRNA625
knockdown affected the expression of 202 genes (141 up- and
61 downregulated; |log (fold change)|4log21.5) (Figure 4a).
In agreement with a potential role of lncRNA625 in regulating
cell invasion and migration, gene ontology analysis of the
differentially expressed genes showed preferential enrichment
for cellular processes such as cell migration, cycle, motion and
adhesion (Figure 4a).
We next focused on exploring cancer-related functional target
genes regulated by lncRNA625, which were related to genes in
GO terms, such as cell invasion and migration (Figure 4a, right).
Figure 4. Gene expression profile analysis after lncRNA625 knockdown. (a) Gene expression profile analysis performed after lncRNA625
knockdown in cells stably transfected with either shlncRNA625 or scrambled shRNA (shscramble). (b) qRT–PCR of a representative panel of
genes in scrambled and silncRNA625 (error bars are s.d., n= 6). (c) PCGs downregulated by lncRNA625 knockdown and significantly
upregulated in RNA-seq samples. (d) PCGs upregulated and downregulated, following lncRNA625 silencing, in RNA-seq samples. Genes boxed
in red are literature-evidenced cancer-related genes. Genes with an asterisk are literature-evidenced ESCC-related genes.
Identification of novel functional lncRNAs
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Most of the genes regulated by lncRNA625 were highly associated
with cancer cell proliferation, invasion and migration (genes
boxed in red in Figure 4a). Use of qRT–PCR for representative
genes from the cDNA microarrays confirmed their dysregulation
of expression (Figure 4b). Of note, many of the genes induced by
lncRNA625, including NEK6,35–38 TNC,39,40 CCNG1,41 HIST1H2BM,42
NCOA443 and KCTD12,44 have known oncogenic properties.
Similarly, known tumor suppressors, such as SAA1,45 S100A9,46,47
ADI148 and CLDN7,49 were consistently upregulated after
lncRNA625 knockdown (Figure 4b). Moreover, most of these
Identification of novel functional lncRNAs
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genes displayed consistent expression pattern in the RNA-seq
data (Figures 4c and d). That is, those upregulated (down-
regulated) PCGs, following lncRNA625 knockdown, were
significantly downregulated (upregulated) in the RNA-seq sample
(P-value = 1.24e− 06 and 0.041, respectively, hypergeometric test).
Taken together, the above analyses, based on high-throughput
gene expression profiling and low-throughput experiments,
demonstrate that lncRNA-625 controls the up- and downregula-
tion of multiple target PCGs to promote cancer cell proliferation,
invasion and migration.
LncRNA625 interacts with EP300 to regulate transcription of
downstream target genes
To determine the mechanism by which lncRNA625 regulates the
transcription of downstream target PCGs, we initially localized
lncRNA625 in ESCC tissue and showed that lncRNA625 was
located in both nucleus and cytoplasm of tumor cells (Figure 5a).
For KYSE510 cell lines, lncRNA625 was predominantly localized in
the nucleus of cells (Figure 5b), suggesting that lncRNA625 could
regulate transcription of downstream target genes through
binding proteins in the nuclear chromatin. Thus, we focused on
48 histone modification related proteins reported to be highly
associated with ESCC.50 LncRNA625-regulated PCGs were poten-
tially regulated by 176 transcription-related regulatory proteins
based on transcription protein analysis using the DAVID tool.51
Interestingly, of these 48 ESCC histone modification proteins,
only the E1a-binding protein p300 (EP300) appeared in 176
lncRNA625-related transcription regulatory proteins (Figure 5b).
Searching the UCSC genome browser, showed that EP300
occupancy frequently appeared in the promoter regions of
multiple lncRNA625-regulated PCGs including NEK6, TNC, NCOA4
and CROT (Supplementary Figure 5). Furthermore, all 202
lncRNA625-regulated genes were compared with a compendium
of published EP300 occupancy profiles in diverse cell types in the
UCSC database (Supplementary Table 6). In several cancer cell
lines, such as HeLa, HepG and SkNSHRA, genes downregulated by
lncRNA625 knockdown were enriched for the endogenous EP300
occupancy pattern, but not enriched in hESC (Figure 5d).
Compared with the upregulated genes following lncRNA625
knockdown, downregulated genes displayed higher statistical
significance scores for EP300 occupancy in cancer cell lines
(Figure 5d, hypergeometric test).
To explore EP300 binding to lncRNA625, catRAPID (http://big.
crg.cat/gene_function_and_evolution/services/catrapid), a predic-
tor of protein-RNA binding, was employed to assess the likelihood
of protein-RNA interaction.52 LncRNA625 (nucleotide positions [nt]
40–140) and EP300 protein (amino acid residues 900–1600) were
predicted to interact (Supplementary Figure 6). Next, we examined
the binding of lncRNA625 and EP300 through RNA immunopre-
cipitation (RIP) in human KYSE150 and KYSE510 cells. LncRNA625
co-precipitated with EP300 in both cell lines (Figure 5e), suggest-
ing that the interaction of lncRNA625 with EP300 mediates the
transcription of target genes.
Secondly, EP300 was silenced and the expression of lncRNA625
target genes was examined. Gene expression profiling of knock-
down samples on cDNA microarrays indicated that EP300 affected
expression of several downstream lncRNA625 target genes
(Figure 5f). Moreover, Gene Set Enrichment Analysis (GSEA)53
showed that genes regulated by lncRNA625 were enriched in the
expression profile after knocking down EP300 (Figure 5g).
Especially, those downregulated genes after knocking down
EP300 received a high enrichment score (ES), suggesting that
lncRNA625 might induce transcriptional responses of genes
through interacting with EP300. We focused our attention on
representative lncRNA625-induced genes involved in enhancing
cancer cell proliferation, invasion and migration. Use of qRT–PCR
confirmed that lncRNA625 induced multiple PCGs, such
as NEK6, TNC, KCTD12, NCOA4, CROT, HIST1H2BM, ASUN and
CCNG1 after silencing of either EP300 or lncRNA625 (Figure 5h),
consistent with the cDNA microarray results. Indeed, most of
lncRNA625- and EP300-induced downstream PCGs evaluated by
qRT–PCR are known positive regulators of cancer, including
NEK6,35–38 TNC,39,40 CCNG1,41 HIST1H2BM,42 NCOA443 and
KCTD12.44 These results demonstrate the key role of EP300 in
executing lncRNA625-induced transcriptional responses of genes,
to promote cancer cell proliferation, invasion and migration.
LncRNA625 constitutes a tumor signature for survival time in
metastatic ESCC
The relationship between lncRNA625 expression and prognosis of
ESCC patients was explored by Kaplan–Meier analysis and log-rank
test. LncRNA625 levels were measured in an independent panel of
118 cases from 120 ESCC patients with extensive clinical follow-up.
Dependent on the lncRNA625 signature, patients were divided
into either a high-risk group (n= 92) or a low-risk group (n= 26).
Patients with high lncRNA625 expression did not have
significantly shorter overall survival (OS) than those with the low
expression. For disease-free survival (DFS), patients with high
lncRNA625 expression had significantly shorter survival time than
those with low expression (median survival 23.2 months vs
480 months, Po0.028; Figure 6a). Thus, high lncRNA625 levels
predicted poor prognosis.
To test whether lncRNA625 has prognostic value within clinical
stages, a stratified analysis was performed on stage III ESCC
patients to evaluate whether the lncRNA625 signature could
predict survival of patients within the same clinical stage.
A log-rank test showed that lncRNA625 could classify patients
with stage III into high- and low-risk groups (Figure 6a). However,
for patients with stage I/II, lncRNA625 level was not a significant
predictor of prognosis (Supplementary Figure 7). Stratified analysis
Figure 5. LncRNA625 interacts with EP300 to regulate downstream target genes. (a) LncRNA625 is located in the cytoplasm and nucleus of
tumor tissue. Sense or antisense probe for lncRNA625 FISH were synthesized by in vitro transcription of T7 RNA polymerase, and 3 μm serial
slides of ESCC tissues were hybridized with sense or antisense probes conjugated with biotin. Subsequently, the biotin signal was determined
with Cy3-conjugated streptavidine. DAPI staining for was for nuclei, and haematoxylin and eosin staining was for tumor histomorphology.
Scale bar: 40 × . (b) Cytoplasmic and nuclear RNAs were isolated from KYSE510 cells, and lncRNA625 was detected by real-time RT–PCR. Levels
of U6 snRNA (nuclear control transcript) and GAPDH (cytoplasmic control transcript) were detected by real-time RT–PCR. Values are
mean± s.e. (c) Venn diagram showing the overlap between ESCC-related histone modification proteins and lncRNA625-related transcription
regulatory proteins. (d) Comparison of 202 differentially expressed genes following silencing lncRNA625 in KYSE150 cells vs. a compendium of
UCSC-published EP300 occupancy profiles in diverse cell types. (e) LncRNA625 interacts with EP300. RNA immunoprecipitation assays for
EP300 were performed and RNA was extracted with 1 ml TRIzol, and lncRNA625 was detected by real-time RT-PCR in both KYSE150 and
KYSE510 ESCC cells. IgG and SP1 were used as negative controls in the experiment. (f) Gene expression profile analysis was performed after
either lncRNA625 or EP300 knockdown in KYSE 150 cells. Genes with |log2FC|4log21.5, after lncRNA625 knockdown, are displayed in the heat
map. (g) GSEA plot showing that genes regulated by lncRNA625 were enriched in the expression profile after knocking down EP300. In
particular, those genes downregulated after knocking down EP300 received a high enrichment score. (h) qRT–PCR of a representative panel of
genes in scrambled, silncRNA625 and siEP300 cells (error bars are s.d., n= 6). Genes boxed in red are literature-evidenced cancer-related
genes. Genes with an asterisk are literature-evidenced ESCC-related genes.
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for patients with invasive depth 1/2 (T1/T2) and non-lymph
node metastasis showed that high lncRNA625 expression did not
confer shorter OS and DFS (Supplementary Figure 7). However,
a stratified analysis for patients with either invasive depth 3/4
(T3/T4) or lymph node metastasis showed that lncRNA625 could
be a significant predictor of subsequent metastasis and death.
Taken together, lncRNA625 showed specific prognostic value for
patients with metastatic ESCC (Figure 6a).
To assess whether the prognostic ability of the lncRNA625
signature is independent of other clinical or pathological factors
of ESCC patients, multivariate Cox regression analysis with
disease-free survival was performed using the Cox proportional
Figure 6. Kaplan–Meier curves of ESCC patients with either higher or lower expression of lncRNA625 and downstream target PCGs.
(a) Kaplan–Meier survival curves of patients with ESCC classified into high- and low-risk groups based on their lncRNA625 signature.
Expression level and survival information were obtained in 118 cases from 120 ESCC patient samples. For patients with invasive depth 3/4
(T3/T4), lymph node metastasis and stage III, a stratified analysis was done. (b) Kaplan–Meier survival based on the lncRNA625 signature for
the cancer lncRNA profiles in TCGA. (c) Kaplan–Meier survival curves of ESCC patients classified into high- and low-risk groups based on two
lncRNA625 downstream target PCG signatures. Expression level and patient information were obtained from TCGA. Red and blue indicates
higher and lower expression, respectively.
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hazards regression mode. Selected co-variables included age,
gender, tumor size, TNM stage and lncRNA625. The results
showed that survival prediction by lncRNA625 levels is
independent of clinical and pathological factors for DFS of
patients with ESCC (Supplementary Table 7).
To assess the prognostic ability of the lncRNA625 signature in
other cancer, lncRNA profiles in TCGA were analyzed. We obtained
lncRNA prognostic results of TCGA from the ‘My lncRNA’ module
in the TANRIC database (http://ibl.mdanderson.org/tanric/_design/
basic/index.html). In the TANRIC database, a total of 15 cancer
types are available for survival analysis. LncRNA625 showed
moderate prognostic value in ovarian serous cystadenocarcinoma
and glioblastoma multiforme patients, with a log-rank test P-value
o0.05 (Figure 6b). For other cancer patients, lncRNA625 level was
not a significant predictor of prognosis (Figure 6b). These
suggested that lncRNA625 has the better prognostic ability in
ESCC than other cancers.
As lncRNA625 showed prognostic value, downstream target
PCGs of lncRNA625 might share a similar prognostic value. To test
this, the mRNA profile of ESCC in TCGA was analyzed. Two
lncRNA625 target PCGs (ASUN and TMPRSS4) showed prognostic
value in ESCC patients (Figure 6c). TMPRSS4 promotes metastasis
in preclinical models,54 and two independent studies have
demonstrated the prognostic value of TMPRSS4 in breast
cancer.55,56 Our analysis determined that ESCC patients with high
TMPRSS4 expression had significantly shorter survival time than
those with low expression (Po0.021). Interestingly, ASUN has not
been reported in cancer. However, ESCC patients with high ASUN
expression had significantly shorter survival time than those with
the low expression (Po0.0019), suggesting that ASUN regulation
by lncRNA625 might be a new marker for poor prognosis of ESCC.
Taken together, lncRNA625 and its downstream target PCGs have
prognostic value for ESCC, especially in patients with metastasis.
DISCUSSION
We describe a comprehensive analysis of lncRNAs in 30
esophageal samples (15 ESCC tissue samples and 15 paired non-
tumor tissues) by massive parallel next-generation sequencing
platforms. Many lncRNAs whose expression patterns distinguish
ESCC from normal tissue were identified, and are co-expressed
with PCGs in the global lncRNA-PCG functional network. The
functions of lncRNAs are closely associated with their abundance
of transcripts and downstream target PCGs directly or indirectly
regulated by them. An effective strategy to identify key lncRNAs is
to develop network-based inference methods, which have
successfully been used for disease PCG and ncRNA identifi-
cation.57–59 Based on an ESCC-associated lncRNA-PCG functional
network, we developed an unsupervised random walk method
using dysregulated lncRNAs/PCGs as seeds for identification of
functional lncRNAs. We focus more on identification of novel key
lncRNAs by considering dysregulated lncRNAs/PCGs as a search
source, and then performing a global search within a tumor-
specific lncRNA-PCG functional network.
Based on URW-LPE, multiple known cancer and many novel
potentially functional lncRNAs were effectively identified in ESCC.
Some known functional lncRNAs, including HOTAIR, ANRIL, DLX6-
AS1, AC130710.1.1, WT1-AS and LINC00261 displayed elevated
URWScores compared with their FC values. As all candidate
functional lncRNAs in ESCC cannot be validated, we focused on
those lncRNAs that displayed highly differential expression and
high rank. LncRNA625 was identified as a representative of a
functional lncRNA in ESCC and was noted to be a novel regulator
of cell invasion and migration in ESCC. Patients with high
lncRNA625 expression had a significantly shorter DFS than those
with low expression. LncRNA625 also displayed specific prognostic
value for patients with metastatic ESCC. We further found that
lncRNA625 interacts with EP300, and that multiple downstream
genes of lncRNA625 are regulated by EP300. Some of these genes,
including NEK6,35–38 TNC,39,40 CCNG1,41 HIST1H2BM,42 NCOA443
and KCTD1244 are associated with cancer. These results demon-
strate that lncRNA625 might have a role in ESCC by interacting
with EP300 to simultaneously upregulate oncogenes and down-
regulate tumor suppressor genes associated with cell proliferation,
invasion and migration in ESCC.
EP300 is a histone acetyltransferase that occupies tissue-specific
transcriptional enhancers.60 EP300 was also reported to be able to
bind lncRNAs such as lncRNA21.61 We found that EP300 regulates
many downstream target genes of lncRNA625. This suggests that
genes upregulated by lncRNA625 and EP300, such as TNC, NEK6,
CCNG1, HIST1H2BM, NCOA4, NCOA4 and KCTD12, are highly likely
to be induced by lncRNA625 via recruitment of EP300 to target
gene promoters. Studies showed that motifs for transcription
factors, such as ETS, FOX, AP1 and STAT, are enriched in EP300-
bound regions, suggesting that complex regulatory mechanism of
lncRNA625 and EP300 might be dependent on other transcription
factors. We modulated the related EP300 network and showed
that the downstream target gene network of lncRNA625 and
EP300 likely very complex, causing numerous changes in global
gene expression in ESCC patients (Supplementary Figure 8). This
demonstrates that it is necessary to use a network-based global
algorithm for identifying functional lncRNAs.
In summary, we used transcriptome sequencing technology to
profile the transcriptomes of both ESCC and non-tumor tissues of
15 Chinese patients. Many novel potentially functional lncRNAs
with high statistical significance were effectively identified by our
URW-LPE method. Of these, lncRNA625 was found to be a novel
biomarker for prognosis of patients with ESCC and to regulate cell
proliferation, invasion and migration through interacting with
EP300. Our findings support an important role for lncRNAs in ESCC
and suggest that functions of these lncRNAs may help to ‘drive’
cancer initiation and progression. Our data provide an important
resource for future studies of key lncRNAs in ESCC and establish
the utility of integrative bioinformatic analyses of RNA-seq to
identify functional cancer-associated lncRNAs.
MATERIALS AND METHODS
Sample collection and preparation
All patients were from the Chaoshan District of Guangdong Province, one
of the high prevalence ESCC areas in China.62 Samples were collected from
the Department of Oncological Surgery of the Central Hospital of Shantou
City, China. Documented informed consent was obtained through the
institutional review board during 2007–2013. Tumor and paired non-tumor
tissues were collected from each patient who underwent surgical
resection; none of the patients were treated with chemotherapy or
radiotherapy before operation. After being examined by a pathologist,
tissues were immediately frozen in liquid nitrogen and stored at − 80 °C.
Partial tissues were used for haematoxylin and eosin staining to confirm
the diagnosis and analysis of pathological grade, metastasis and tumor cell
content. All tumor samples contained more than 80% free of necrosis.
Cases were classified according to the tumor-node-metastasis (TNM)
classification of the International Union against Cancer, 7th edition.
Evaluation of tumor differentiation was based on histological criteria of the
guidelines of the WHO Pathological Classification of Tumors. This study
was approved by the Ethics Committee of the Central Hospital of
Shantou City.
RNA-seq library preparation
Total RNA was isolated using an RNeasy mini kit (Qiagen, Hilden, Germany)
and analyzed on 1% formaldehyde-denatured agarose gels to ensure no
degradation occurred. Paired-end libraries were synthesized by using the
TruSeq RNA Sample Preparation Kit (Illumina, USA) following the TruSeq
RNA Sample Preparation Guide. Briefly, poly-A containing mRNA was
purified using poly-T oligo-attached magnetic beads. Following purifica-
tion, the mRNA was fragmented into small pieces by using divalent cations
at 94 °C for 8 min. The cleaved RNA fragments were copied into first strand
cDNA using reverse transcriptase and random primers, followed by second
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strand cDNA synthesis using DNA polymerase I and RNase H. cDNA
fragments underwent an end repair process, the addition of a single
‘A’ base, and then ligation of the adapters. Products were purified and
enriched by PCR to create the final cDNA library. Purified libraries were
quantified using a Qubit 2.0 Fluorometer (Life Technologies, Carlsbad, CA,
USA), and validated with an Agilent 2100 bioanalyzer (Agilent Technolo-
gies, Santa Clara, CA, USA) to confirm the insert size and calculate the mole
concentration. A cluster was generated by cBot, with the library diluted to
10 pM, and then inserts were sequenced on the Illumina HiSeq 2500
(Illumina, San Diego, CA, USA). Library construction and sequencing was
performed at the Shanghai Biotechnology Corporation. Transcriptome
sequencing data are available publicly at the Sequence Read Archive
(http://www.ncbi.nlm.nih.gov/sra/) under accession number SRP064894.
Identification of esophageal cancer-related lncRNAs and coding
genes
Expression profiles of 15 paired ESCC and non-tumor samples were
extracted by using Tophat (v2.0.6, Tophat, Washington, MD, USA) and
easyRNAseq version 1.6.0 (Heidelberg, Germany), in which the lncRNAs and
PCGs were included. Then, we used DESeq version 1.14.0 (Heidelberg,
Germany) to identify the differentially expressed lncRNAs and coding
genes based on the count number expression profile, and we used the fold
change method to estimate the differential significance of lncRNAs and
coding genes based on the RPKM expression profile. In this study,
esophageal cancer-related differentially expressed lncRNAs/coding genes
are defined as the lncRNAs/coding genes with a fold change 42 or o½,
and a DESeq FDR value o0.25.
Construction of the ESCC-associated lncRNA-PCG functional
network
The ESCC-associated lncRNA-PCG functional network belongs to an
extended lncRNA-PCG co-expression network. First, an ESCC-specific
lncRNA-PCG co-expression network was constructed based on differen-
tially expressed lncRNAs and PCGs. We calculated the Pearson correlation
coefficient between the differentially expressed lncRNAs and PCGs. P-value
of Pearson correlation coefficient of each lncRNA-PCG pair was evaluated
by Fisher’s asymptotic test, which is implemented in the WGCNA R
package of version 1.34, and Bonferroni correction method was used to
control the false discovery rate. Second, protein interaction data was
collected from the HPRD database and the lncRNA-protein interaction data
from the NPInter v2.0 database. The protein interaction data in HPRD
(http://www.hprd.org/) has been manually extracted from the literature by
expert biologists. The NPInter database (http://www.bioinfo.org/NPInter)
contains experimentally verified interactions between non-coding RNAs
and proteins. PCG-PCG interactions were extracted from the co-expression
data and HPRD database. Specifically, if the corrected co-expression
P-value of two differential PCGs was less than 1.0e− 7 or they had direct
interaction in the HPRD network, the PCG interaction pair was extracted.
Similarly, we extracted the lncRNA-PCG interaction pairs if the corrected
co-expression P-value of the differential lncRNA and PCG was less than
1.0e− 7 or they had direct interaction in the NPInter network. Finally, the
ESCC-associated lncRNA-PCG functional network was constructed by
combining the extracted lncRNA-PCG and PCG-PCG interaction pairs.
URW-LPE
We developed an integrative bioinformatics method, denoted URW-LPE,
for identification of functional lncRNAs in ESCC (URW-LPE is available at
https://github.com/LICLAB/URW-LPE). In brief, a random walk was run with
each dysregulated lncRNA/PCG as a seed and an extended co-expression
relation as an edge. First, an extended lncRNA-PCG co-expression network
was constructed based on differentially expressed lncRNAs and PCGs in
ESCC. Second, we ran the random walk for the network, considering the
fold change (FC) values of each node on the network as the initial
probability vector. As a result, each lncRNA in the network would be given
an URWScore value. The higher URWScore value of lncRNAs represents
more important functions in ESCC. Finally, the FDR-corrected P-value for
each lncRNA in the network was calculated through comparison of the real
URWScore of each lncRNA and that of the background distribution. This
method can identify lncRNAs based on global network information, which
usually represents indirect target relations. Compared with other methods,
we focused more on considering dysregulated lncRNAs/PCGs as a
search source, and performing global searching within the ESCC-specific
lncRNA-PCG co-expression network.
Specifically, we used a variant of the random walk with a restart of
probability r in each iterative step, and the fold change values of each
node on the network were considered as the initial probability vector. The
formula of the random walk can be represented as follows:
ptþ1 ¼ 1 - rð ÞWpt þ rp0
where W is the adjacency matrix of the lncRNA-PCG co-expression
network, which has been row-normalized, pt is a vector that the element of
which represents the probability of the corresponding lncRNA and PCG
nodes at step t, p0 is the initial probability vector (used as the setting seed).
In previous methods, p0 was constructed according to known disease
lncRNAs (or genes).22 However, for many diseases, such as ESCC, only a few
lncRNAs are available to be used as seeds, which causes decreased
predictive power for a single disease. We thus used each dysregulated
lncRNA/PCG as a seed, but with a different importance score according to
the fold change (FC) value. Specifically, p0 was constructed according to
the fold change value of nodes. For a given node i (lncRNA or PCG), we
define p0 as the initial probability of node i, which is computed as follows:
p0i ¼ lg 1þ lg 1þ absðFCiÞð Þð Þ
where FCi is the log2-transformed fold change value of node i. Finally, each
differential lncRNA was given an URWScore value. The higher URWScore
value of lncRNAs, the more important functions in ESCC.
To identify the statistically significant lncRNAs, P-values for each lncRNA
in the network were calculated through comparison of the real URWScore
of each lncRNA and that of the background distribution. For lncRNAs in the
network, we randomly generated FC values of each lncRNA from a normal
distribution with the same mean and s.d. as the real FC values of lncRNAs.
For PCGs in the network, FC values of PCGs in the network were shuffled.
The URWScore of each lncRNA was re-computed using the above random
walk method. A total of 1 230 000 (615× 2000) URWScores of lncRNAs was
generated and used as the background distribution. The P-value is the
fraction of the number of lncRNAs, which is larger than that in the real
URWScore. FDR-corrected P-values for each lncRNA in the network were
calculated using the Benjamini–Hochberg FDR method.
Cell culture
The SHEEC human ESCC cell line and SHEE immortalized human
esophageal cell line were established in our laboratory63 and maintained
in DMEM/F12 (1:1) medium containing 10% newborn bovine serum. The
KYSE150, KYSE450, KYSE510 human esophageal cancer cell lines were
kindly provided by Dr. Ming-Zhou Guo (Chinese PLA General Hospital,
Beijing, China) and cultured in RPMI-1640 medium supplemented with
10% fetal bovine serum. KYSE150, KYSE450 and KYSE510 cells were derived
from human esophageal cancer cells. The HEK293T human embryonic
kidney cell lines and NIH3T3 mouse embryonic fibroblast cells were kindly
provided by Professor Dong Xie (The Institute for Nutritional Sciences,
Chinese Academy of Sciences, China). HEK293T cells were derived from
human embryonic kidney cells and NIH3T3 was derived from mouse
embryonic fibroblast cells. All the cell lines were authenticated by STR
profiling and tested for mycoplasma contamination and grown at 37 °C
under a humidified atmosphere of 5% CO2.
Human lncRNA625 cloning and expression plasmid construction
RNA was extracted and contaminating genomic DNA was removed by
DNase I. The cDNA synthesis was performed using a cDNA synthesis kit
(6210A, Takara, Dalian, China), and the reverse primer was used as the
gene-specific primer during the cDNA synthesis. The full-length 577-bp
lncRNA625 transcript (chromosome 15:62, 682, 916-62, 690, 448, reverse
strand) was amplified by PCR using Pfu DNA polymerase (Transgene,
Beijing, China) with the forward primer containing a Hind III site and the
reverse primer containing a Not I site. The PCR product was cloned into the
pcDNA3.1 eukaryotic expression vector (Life Technologies) and confirmed
by sequencing.
Transfection of siRNAs and plasmids
KYSE150 or KYSE510 cells were inoculated in a 12-well plate, containing
antibiotic-free medium, for 24 h to achieve the desired density of 30-50%
confluence prior to transfection. The siRNA oligos were synthesized by
GenePharma (Shanghai, China). For small interfering RNA, 1.6 μg siRNA
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oligos and 8 μl transfection reagent (Roche, Indianapolis, IN, USA) were
mixed in Opti-MEM culture medium (Life Technologies), and the mixture of
siRNA and transfection reagent was added to each well. The procedure for
transfection was performed according to the protocol provided by the
transfection reagent supplier. For the lncRNA625 construct, 70-90%
confluence was achieved at the time of plasmid transfection and 1.6 μg
lncRNA625 expression plasmid and 4.8 μl Lipofectamine 3000 transfection
reagent (Life technologies) were used per well. The sequence of siRNA
oligos used in this study was as follows: lncRNA625: 5′-GACCACCAUCAAGG
GAUAAdtdt-3′ (sense); 5′-UUAUCCCUUGAUGGUGGUCdtdt-3′ (antisense).
EP300:5′-ACAGCUGUCAGAAUUGCUGdtdt-3′ (sense); 5′-CAGCAAUUCUGAC
AGCUGUdtdt-3′ (antisense). Scrambled RNA (negative control):5′-UUCUC
CGAACGUGUCACGUdtdt-3′ (sense); 5′-ACGUGACACGUUCGGAGAAdtdt-3′
(antisense).
Construction of stable shlncRNA625-expressing cells
A shlncRNA625 lentiviral vector was constructed by Hanbio (Shanghai,
China) according to the above siRNA oligo sequence against lncRNA625.
KYSE150 or KYSE510 cells were inoculated in a 24-well plate, containing
normal culture medium, at 2.5x104 cells per well. The next day, 5 μl
lentiviral solution containing shlncRNA625 vector was mixed with 250 μl
normal culture medium with polybrene (Sigma-Aldrich, St Louis, MO, USA)
at a final concentration of 6 μg/ml, and then the mixture was used to infect
cells after the removal of the previous culture medium. After 4 h, an
additional 250 μl normal medium with polybrene was added to each well.
The virus-containing culture medium was removed at 24 h post-transfec-
tion, fresh medium was added for an additional 24 h. and then cells were
refed with culture medium containing puromycin (final concentration
500 ng/ml). The level of lncRNA625 on the fifth or sixth passage was
quantified by real-time RT–PCR in order to screen multiple cell clones for
lncRNA625 knockdown. Control cells were obtained by infection with virus
encoding a scrambled short hairpin RNA.
Invasion, migration and colony formation assays
KYSE150 or KYSE510 ESCC cells were subjected to lncRNA625 knockdown
or upregulation by either RNA interference or overexpression of
lncRNA625, respectively. At 24 h post transfection, cells were starved for
12 h with serum-free culture medium and then cell invasion, migration and
colony formation assays were performed according to previously
described methods.64,65 Briefly, 5 × 104 cell were plated in medium without
serum in the upper well of a transwell chamber with (for cell invasion) or
without (for cell migration) a Matrigel-coated membrane (24-well insert;
pore size, 8 μm; BD Biosciences, Franklin Lakes, NJ, USA), and with the
lower chamber containing medium supplemented with 10% serum. The
cells were incubated for 48 h and the cells in the top transwell chamber
that did not invade or migrate through the pores were removed with a
cotton swab. Cells that invaded or migrated through the pores were fixed
and stained with haematoxylin solution, and counted. Stable cell lines
expressing either shlncRNA625 or control lentiviral vector were used in
identical cell invasion and migration assays. For colony formation assays,
1x103 cells/per well were inoculated in each well, of a six-well plate,
containing medium+10% fetal bovine serum. Colonies were stained with
haematoxylin solution and observed after incubation for 15 days.
Tumor xenografts
Animal experiments were approved under the guidelines of the Animal
Policy and Welfare Committee of Shantou University Medical College.
Six-week-old female BALB/c nude (nu/nu; n= 9) mice purchased from
Beijing Weitonglihua Company in China were anesthetized with an
isoflurane/propylene glycol mixture and KYSE150-shlncRNA625 or
shscramble stable cells were subcutaneously injected into the right flanks
(1.0 × 106 cells/mouse). After one week, the tumor volume was measured
every two days according to the formula V= ab2/2 (‘a’ means the length of
tumor tissue and ‘b’ means the width of tumor tissue). All mice were
euthanized using the inhalation of CO2 at three weeks and tumors were
collected and weighed.
Reverse transcription (RT) and real-time PCR
Total RNA was extracted using TRIzol (15596-018, Life Technologies) and
purified with a PureLinkTM RNA Mini Kit (12183018A, Life Technologies)
according to the manufacturer’s protocol. The purity and concentration
of RNA were determined by OD260/280 using a NanoDrop ND-2000
spectrophotometer. cDNA synthesis was made by reverse transcription,
and real-time PCR was performed by using a SYBR Premix Ex Taq kit
(DRR037A, DRR081A; Takara). Briefly, reverse transcription was performed
according to the following conditions: 37 °C, 15 min; 85 °C, 5 s. Real-time
PCR was performed using an ABI 7500 real-time PCR system (Life
Technologies) according to the following conditions: 95 °C, 30 s; 95 °C,
5 s; 60 °C, 34 s. Relative quantification of mRNA expression was calculated
by the 2-ΔCt method.
LncRNA625 detection in cytoplasmic and nuclear extracts
Cytoplasmic and nuclear extracts were prepared according to an online
protocol (http://www.lifetechnologies.com/cn/zh/home/references/protocols/
cell-and-tissue-analysis/elisa-protocol/elisa-sample-preparation-protocols/
nuclear-extraction-method-.html). The cytoplasmic extract was mixed with
chloroform and centrifuged at 12 400 g and 4 °C after vortexing. The upper
layer was collected, and RNA was isolated with an RNA extraction kit (DP419,
Tiangen Biotech, Beijing, China). RNA from the nuclear extract was extracted
by using TRIzol (Life Technologies), and lncRNA625 was subjected to reverse
transcription and real-time PCR. Cytoplasmic and nuclear extracts from
KYSE510 cells were prepared, and U6 snRNA was used as the nuclear control
and GAPDH mRNA was used as the cytoplasmic control transcript.66
Fluorescence in situ hybridization
The PCR product used as the template for lncRNA625 fluorescence in situ
hybridization (FISH) probe synthesis was amplified according to the
appropriate reference.67 Briefly, we designed the forward primer with T7
promoter sequence for sense probe synthesis and the reverse primer with
T7 promoter sequence for antisense probe and then the pcDNA3.1-
lncRNA625 vector was used as the template to amplify the PCR product for
FISH probe synthesis. The primers for sense probe synthesis were as
following: Forward:5′-GATCACTAATACGACTCACTATAGGGAGAGACCACCAT
CAAGGGATAAAAT-3′; Reverse:5′-GGCTAATAAACAGGGTCTTCAGGT-3′; the
primers for antisense probe synthesis were 5′-AGAGACCACCATCAAGGGAT
AAAAT-3′(Forward), 5′-GATCACTAATACGACTCACTATAGGGGGCTAATAAAC
AGGGTCTTCAGGT-3′(Reverse). FISH probe synthesis was performed
according to the following condition: 1 μg PCR product, 2 μl T7 RNA
polymerase, 2 μl 10 × buffer, 2 μl biotin RNA labeling mix, 0.5 μl RNase
inhibitor and water was added to total 20 μl volume. The mix was
incubated at 37 °C for 2 h and the probes were diluted with deionized
formamide at 1:5.
FISH assays were performed using the method the reference provided
with minor modification.68 Three-μm tissue sections were subjected to
deparaffinization and dehydration. After 0.1 N HCl treatment, tissue
sections were heated in citrate buffer (pH 6.0) for 20 sec every 2 min in a
microwave for a total of 12 min and were subsequently digested using
proteinase K at 20 μg/ml for 20 min at 37 °C, and then the tissues were
fixed in 4% paraformaldehyde for 10 min at room temperature. Sections
were prehybridized for 2 h at 37 °C in hybridization buffer: 1 μl DTT, 50 ×
Denhardt's solution (Suolaibao, Beijing, China), 1 μl salmon sperm ssDNA
(Life Technology), 2 μl 20 × SSC, 10 μl deionized formamide, 2 μl 50%
sodium dextran sulphate). The FISH probes, sense or antisense probe for
lncRNA625, were added to hybridization buffer. After denaturation at 80 °C
for 10 min, the probes were incubated with tissue sections overnight
at 48 °C and then sections were washed in 2 × SSC containing 50%
formamide and 2× SSC twice at 37 °C for 15 min. Cy3-conjugated
streptavidin (ThermoFisher Scientific, Hudson, NH, USA) was subsequently
incubated with the slides at room temperature for 1 h, and then
fluorescent signals were observed with a fluorescence microscope Axio
Imager A2 (Zeiss, Bochum, Germany) after DAPI staining. Serial slides were
stained with haematoxylin and eosin to confirm tumor histomorphology.
RNA immunoprecipitation
RNA immunoprecipitation was performed according to a modified method
of Yoon et al.66 Briefly, KYSE150 and KYSE510 cells were lysed in lysis buffer
(20 mM Tris-HCl, pH 7.5, 100 mM KCl, 5 mM MgCl2, 0.5% NP-40, protease
inhibitors, 200 U/ml RNase inhibitor) for 15 min on ice, and then
supernatants were collected by centrifugation at 10 000 g for 15 min at
4℃. To completely lyse the nuclear membrane, the pellet was vortexed at
4℃, and then cell debris was removed by centrifugation at 16 000 g for
10 min. All supernatants were combined and 10% of the combined
supernatant was used as input and equivalent quantities of supernatants
were incubated overnight at 4℃ with magnetic beads coated with protein
G and antibodies, recognizing either rabbit anti-EP300 (sc-585, Santa Cruz
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Biotechnology, Santa Cruz, CA, USA), rabbit anti-SP1 (ab13370, Abcam,
USA), or rabbit normal control IgG (sc-2027, Santa Cruz Biotechnology). The
next day, the magnetic bead complexes were subjected to extreme
washing with lysis buffer and RNA was extracted with TRIzol (Life
Technologies). RNA from 10% input was also extracted by TRIzol.
Contaminating genomic DNA in the extracted RNA was removed by
DNase I before reverse transcription, and real-time RT-PCR was subse-
quently performed using a PrimeScript RT reagent kit with gDNA Eraser.
Real-time PCR for lncRNA625 was performed with a SYBR Premix Ex Taq kit
(RR047A, DRR081A; Takara).
cDNA microarray assay
Stably transfected KYSE150 cells, transfected with shlncRNA625 or
shscramble, were collected and lysed in TRIzol (Life Technologies), and
EP300 from human KYSE150 cells was subjected to knockdown by siRNA
interference. Microarray experiments were performed by following the
Affymetrix protocol at the Shanghai Biotechnology Corporation. Total RNA
was isolated and purified by using an RNeasy Total RNA Isolation Kit and
RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. Total RNA was checked for a RIN number to inspect RNA
integration by an Agilent Bioanalyzer 2100 (Agilent technologies). RNA
samples from each group were then used to generate biotinylated cRNA
targets for the Affymetrix GeneChip Human Transcriptome Array 2.0. The
biotinylated cRNA targets were then hybridized with the microarray. After
hybridization, arrays were stained in a Fluidics Station 450 and scanned on
an Affymetrix Scanner 3000. Fluorescent signal intensities for all spots on
the arrays were analyzed using a Gene Chip Operating System (Affymetrix,
Cleveland, OH, USA). Ratios were calculated between either shlncRNA625
and shscramble, or siEP300 and shscramble. Genes with a fold change of at
least two were selected for further analysis. The selected genes were
grouped in functional categories based on the Gene Ontology database
(GO: http://www.geneontology.org/). cDNA microarray data are available
publicly at Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/)
under accession number GSE74707 and GSE74742.
Statistical analysis
Statistical analyses were performed using SPSS 19.0 (IBM, Chicago, IL, USA)
or R 3.1.2 (Auckland, New Zealand) for Windows. Comparisons of the
relative expression of lncRNAs, between paired tumor and non-tumor
tissues, were performed using a paired t-test and the above statistical
method was also used for the statistical analysis of tumor volume and
weight from the tumor tissues in mice xenograft. The comparisons
between shscramble and siRNA cells were performed using the Mann–
Whitney U-test. Overall survival time or disease-free survival time was
calculated by the Kaplan–Meier method and analyzed by the log-rank test.
Overall survival was measured from the date of surgery to death from any
cause, and disease-free survival was measured from the date of surgery to
disease progression or relapse. The optimal cutpoint for lncRNA625
expression was assessed by the X-tile program.69 Univariate and multi-
variate analyses were based on the Cox proportional hazards regression
model. A two-tailed P-value o0.05 was considered to have statistical
significance.
Transcript profiling
Transcriptome sequencing data are available publicly at the Sequence
Read Archive (http://www.ncbi.nlm.nih.gov/sra/) under accession number
SRP064894. cDNA microarray data are available publicly at Gene
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under accession
number GSE74707 and GSE74742.
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